Royalty Report: Drugs, Biotechnology, Cancer – Collection: 7601

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Biotechnology
  • Cancer
  • Wound Care
  • Diagnostic
  • Test/Monitoring
  • Medical
  • Supply
  • Therapeutic
  • HIV / AIDs
  • Delivery
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7601

License Grant
University grants to Licensee and its Affiliates under the Licensed Patents an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory.
License Property
Invention Disclosures

10031C –Methods and Uses to Alter Neuronal Stem Cell Fate

10037C — Use of soluble Fas (CD95) in cyanoacrylate to promote wound healing and as a wound sealant (no patents filed under this number)

10038C — Promotion of diabetic wound healing by incorporation of insulin in a cyanoacrylate wound sealant (no patents filed under this number)

10039C — Use of soluble FasL in cyanoacrylate to promote wound healing and as a wound sealant (no patents filed under this number)

10040C –Wound healing promotion by delivery of colloidal silver in a cyanoacrylate wound sealant

2002.012C –Use of Low Frequency Microwave for Repair of Central Nervous System Injury Including Stroke, Trauma, Alzheimers, Parkinson's Disease, Multiple Sclerosis

2002.013C — Use of Low Frequency Microwaves to Alter Plasma Membrane Potential in Cells in Diseases (no patents filed under this number)

2002.014C –Use of Low Frequency/Intensity Microwaves in Combination with Metallic Particles to Enhance the Effect of Microwaves on Electron Transport and Mitochondrial Function (no patents filed under this number)

2002.015C –Use of 2-deoxyglucose to Promote the Effectiveness of Low Frequency/Intensity Microwaves to Alter Mitochondrial Function (no patents filed under this number)

2002.016C –Use of Low Frequency Microwaves to Alter Electron Transport in Mitochondria of Wounds (no patents filed under this number)

2002.017C — Use of Low Intensity Microwaves to Modulate Expression and Transport of Costimulatory Molecules (no patents filed under this number)

2002.018C –Use of Low Frequency/Intensity Microwaves as a Method for the Detection of Breast Cancer Cells (no patents filed under this number)

2002.019C –Use of Low Intensity Microwaves to Treat Type I and Type II Diabetic Neuropathies, Nephropathies, Pathologies of the Eye, Muscle Wasting, and Wound Healing (no patents filed under this number)

2002.020C –Use of Low Frequency Microwaves to Treat Cancers in Concert with Immunological Therapeutics (no patents filed under this number)

2002.021C –Use of Low Frequency Microwaves as a Method of Augmenting Traditional Chemotherapeutic Techniques and/or Traditional Radiation Therapy (no patents filed under this number)

2002.022C –Methods and Uses of Radio Protection Using Small Acidic Spore Protein and Human and Animal Analogs of Small Acidic Spore Protein (no patents filed under this number)

2002.023C — Method of Promoting, Preventing, Sustaining, or Shortening Neural Synapse by Manipulation of Mitochondrial, Liposomal, or Plasma Membrane Uncoupled (no patents filed under this number)

2002.030C –Methods and Products to Lower, Increase, or Remove Cell Surface Costimulatory Molecules by Altering Levels of Intracellular Reactive Oxygen Intermediates (no active patents)

2002.031C –Use of Inhibitors or Promoters of 2, 4 dienoyi-CoA-reductase to Promote or Prevent Reactive Oxygen Production

2002.032C –Use of Inhibitors or Promoters of 2,4 denoyi-CoA-isomerase to Promote or Prevent Reactive Oxygen Production (no patents filed under this number)

2002.033C — Use of Probiotic Delivery of Self Antigens for Immunological therapy in Autoimmune Diseases/Use of Various Strains of Probiotics to Determine Cytokine Bias (no patents filed under this number)

2002.034C — Use of Oral Administration ofT Cell Receptor Peptides Expressed in Probiotic Delivery System to Induce Therapeutic Immune Responses as Indicated (no patents filed under this number)

2002.035C –Use of Ligands for B7.1, B7.2, CD28, or CTLA4 in Cyanoacrylates to Promote Wound Healing (no patents filed under this number)

2002.036C — Use of Microwaves and Cyanoacrylate to Promote Wound Healing (no patents filed under this number)

2002.081C –Methods and Uses to Alter Neuronal Stem Cell Fate by Manipulation of Uncoupling Protein(s)

2002.119C –A Means of Preserving Organs, Tissue, and Stem Cells for Transplant, and for Improving the Success of Transplantation (no patents filed under this number)

CU1008C –Methods for Lowering Costimulatory Molecule Expression on Embryonic Stem Cells through Modulations of Oxidant Levels in the Cell with or without TCR Peptide or Other Peptide Vaccination (no patents filed under this number)

CU1014C –Method to Determine Rates of Cellular Division, Apoptosis, Oncosis or Growth Arrest through Use of Flow Cytometry (no patents filed under this number)

CU1047C –The use of saturated and polyunsaturated fatty acids to promote the effectiveness of gamma interferon as an immunogenic agent (no patents filed under this number)

CU1048C –A Diagnostic Screen of Peripheral Blood as an Indicator of Metabolic Dysfunction and Consequent Altered Immunity Disease (no patents filed under this number)

CU1049C — Use of polyphosphorylated nucleotides to change metabolic base states in cells (no patents filed under this number)

CU1050C –Methods and uses to induce or inhibit translocation of uncoupling proteins to and from cellular sites including plasma membrane organelles (no patents filed under this number)

CU1063C –Use of Fas Engagement and Selective Fatty Acids to Promote or Prevent Cell Viability Through Induction of Active Uncoupling Proteins Activity (no patents filed under this number)

CU1065C — Microinjection of Mitochondria Into Stem Cells, Growing Cells, or Dysfunctional Cells as a Therapeutic Manipulation in Diseases (no patents filed under this number)

CU1081C –Biochemical Process for the Separation of Toxic Substances, Including Heavy Metals Contained in Circuit Boards (no active patents)

CU1098C –A Therapeutic Approach to Pathogenesis of Down Syndrome (no patents filed under this number)

CU1099C –Blood Test for Early Detection of Down Syndrome (no patents filed under this number)

CU1105C — Micro/Nano Devices and Nanoparticles and Implants for Detecting and Altering Cellular and Tissue Metabolism (no patents filed under this number)

CU1125C –Methods and uses to protect or destroy nuclear DNA by manipulations of a newly discovered nuclear membrane uncoupling protein (UCP) or uncoupling-like protein/molecule (no patents filed under this number)

CU1128C –NUCLEI Methods and Uses to Protect or Destroy Nuclear DNA by Manipulations of a Newly Discovered Nuclear Membrane Uncoupling Protein (UCP) or Uncoupling-Like Protein Molecule (no patents filed under this number)

CU1138C — Novel Therapies for Tissue Repair, Remodeling, Reconstruction and Regeneration

CU1244C –Methods and Uses to Kill Tumor Cells In Vivo Using a Toxin Derived from the Black Widow Spider, Latrotoxin (no patents filed under this number)

CU1245C –The Use of Genistein to Supplement the Activity of Chemotherapeutic and Metabolic Modifying Agents (no patents filed under this number)

CU1246C –Use of Myxococcus Xanthus to Eliminate the Environmental Toxicity of Methane Production by Methanobacteria (no patents filed under this number)

CU1248C –Computer Software for Improved Flow Cytometric Data Analysis (no active patents)

CU1249C — Cybenetic Biovitiation (no patents filed under this number) CU1344C –Array for Metabolic Analysis (no active patents)

CU1518C — Myxococcus xanthus derived oncolytic agent (no patents filed under this number)

CU1696H –Induction of apoptosis in tumor cells (no patents filed under this number)

CU1715C –Metabolic Modifications in Plants as a Mechanism for Increasing Plant derived Ethanol or Oil for Fuel Production

CU1968C –Inhibition of Fatty Acid Oxidation (FAO) to potentiate drug sensitivity in breast cancer

CU2407H –Systems and Methods for Treating Human Inflammatory and Proliferative Diseases and Wounds, with a Combination of Chloroquine and a Glycolytic Inhibitor

CU2421H –Proteins for Use in Diagnosing and Treating Infection and Disease

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 240481

License Grant
University grants to Licensee an exclusive license of University's interest under the Licensed Patents for the purpose of making, having made, manufacturing, importing, using, marketing and selling Licensed Products, solely within the Licensed Field, in the Territory, with the right to grant sublicenses to Affiliates and Sublicensees.
License Property
Licensed Patents means any of the following to the extent that University has, or at any time acquires, the right to grant licenses thereto
(a)  any patent or patent application which claims priority from any of the following patent applications (a) USSN 07/275,433, filed 11/23/88; (b) USSN 07/864,805, filed 4/7/92; (c) USSN 07/864,866, filed 4/7/92; (d) USSN 07/864,807, filed 4/7/92; including all foreign equivalent patent applications and Patent Cooperation Treaty filings, and all patents issuing therefrom in which University has a property interest.
(b)  the following rights, all to the extent covering inventions to which inventive contributions were made as of May 28, 1992 (solely or jointly) by former University faculty member Craig B. Thompson in the scope of his duties for University and the Howard Hughes Medical Institute U.S. Patent No. 5,434,131 (the '131 Patent') and/or U.S. Patent No. 5,521,288 (the '288 Patent') and (a) any patent applications or patents issuing therefrom claiming or entitled to priority from an application from which the 131 Patent or 288 patent issued.

5,434,131 – Chimeric CTLA4 receptor and methods for its use
5,521,288 – CD28IG fusion protein

Field of Use
Licensed Field means the Licensee Field as defined in the agreement made by and between the Parties and GI (Genetics Institute) on November 17, 1999. The Parties acknowledge and agree that GI has an exclusive and nonoverlapping license·to the University Patents outside of the Licensed Field.

CTLA4 is a key regulator of the activity of the immune system which 'turns off' the immune system after it has successfully cleared a bacterial or viral infection by blocking the activation of T-cells, the immune cells responsible for activating an immune response. Animal and human studies have suggested that a soluble form of CTLA4 ('CTLA4-Ig') may be useful in treating diseases such as rheumatoid arthritis, multiple sclerosis, lupus, psoriasis and organ transplant.

IPSCIO Record ID: 6107

License Grant
Licensor hereby grants to Licensee a non-revocable, royalty-bearing exclusive right within the Territory to the Patent Rights in the Field, including the right to sublicense to third parties within the Field, provided that any third party sublicensee shall be subject to all of Licensee's obligations.
License Property
The Parties entered into a joint patent ownership and License Agreement dated as of August 16, 2004, which was later amended and restated as of May 23, 2006, for consideration the sufficiency of which was acknowledged in each Agreement, pursuant to which Licensor granted Licensee a 50% ownership interest in certain patents and patents applications listed in the Joint Ownership Agreement, as well as certain future patent rights, and the parties acknowledge that Licensee would have exclusive rights within a defined filed, while Licensor would have exclusive rights outside that field. Licensee and Licensor now wish to enter a new Agreement superseding the Joint Ownership Agreement so as to specify those future patents and patent applications that are to be subject to joint ownership and so as to restate the Licenses granted in the Joint Ownership Agreement. The Parties acknowledge that the jointly owned and cross-Licensed rights are vital to the parties’ respective plans for development and commercialization and wish to further clarify the parties’ respective rights and provide for continued access to the necessary rights in the event of insolvency.

Jointly Owned Patent Applications shall mean the pending Foreign Patent Applications listed below, including any foreign national patent applications which claim priority to the Foreign Patent Applications and any Future Patent Applications, including any continuations, divisionals, re-exams, reissues and continuations-in-part and any other forms of related applications, that claim domestic or international priority to any of the Issued United States or foreign patents, or pending international or foreign patent applications, specifically listed by patent or application number herein.

(a) Issued US Patents

(i) U.S. 6,268,178 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides; and

(ii) U.S. 6,642,026 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.

(iii) U.S. 6,773,899 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(iv) U.S. 6,794,162, entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(b) Foreign Patent Applications

(i) International Patent Applications. All foreign patent applications related to the above-referenced U.S. patents and applications and claiming priority to the following international patent applications under the Patent Cooperation Treaty (PCT)

A. International Patent Application No. PCT/US00/40020, published as International Publication No. WO 00/71731 A2 on November 30, 2000 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides.

Field of Use
The Licensee plans to develop and commercialize therapeutic methods related to the induction of angiogenesis or wound healing by administration of Fibroblast Growth Factor (FGF); and, the Licensor plans to develop and commercialize recombinant DNA methods for producing peptides/proteins.

Field shall encompass any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions. CARDIO-developed devices and methods of use thereof for delivery of angiogenic or wound healing compositions are not included within the Field, and are not subject to joint ownership or any other terms of this Agreement.

IPSCIO Record ID: 7597

License Grant
Therefore the Licensor, a University, grants an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory to the Licensee
Licensee may sublicense the rights granted.
License Property
The invention relates to methods for modulating the immune function through targeting of CLIP molecules.

Invention Disclosures
CU1760C- Selective Modulation of Gamma Delta T Cells to Treat Autoimmune Diseases, HIV, and Cancer
CU1969C – Competitive inhibitors of Invariant Chain expression and/or ectopic CLIP binding
CU1971C- Use of soluble H-2M (HLA-DM) as a CLIP displacement therapy (combined with CU1969C and patents filed under CU1969C)
CU2131C- Topical HIV prevention cream/gel (provisional application was abandoned as it was covered under applications filed in CU1760C and CU1969C)
CU2253C – The use of non-specific CLIP displacing peptides to treat or prevent chronic disease mediated by infectious organisms (no patents filed yet)
CU2254C – The use of peptides derived from an infectious organism that displace CLIP in order to treat or prevent chronic conditions mediated by those very organisms (no patents filed yet)

Patent Applications
Country
Serial No
File Date
Title
lnternal ID

United States
60/886,852
01/26/2007
Methods of Modulating Immune Function Through Targeting of Invariant Chain/CD74 and Clip
CU1760C- PPA1

United States
60/906,731
03/13/2007
Immune Mechanism For The Depletion of CD4+ T Cells
CU1760H- PPA2

PCT
PCT/US2008/001097
01/28/2008
Methods of Modulating Immune Function
CU1760C- PCT1

United States
12/011,643
01/28/2008
Methods of Modulating Immune Function
CU1760C-US2

United States
12/021'118
01/28/2008
Methods of Modulating Immune Function
CU1760C-US1

United States
61/191,740
09/11/2008
The Immune Response to HIV
CU1760C- PPA3

Country
Serial No
File Date
Title
lnternal ID

United States
61/000,152
10/23/2007
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C- PPA1

United States
61/135,942
07/25/2008
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C- PPA2

United States
61/135,964
07/25/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1996C- PPA3

United States
61/137,150
07/25/2008
Methods for Treating Viral Disorders
CU1969C-PPA4

PCT
PCT/US2008/012078
10/23/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C-PCT1

United States
15/508,554
07/23/2009
Methods for Treating Viral Disorders
CU1969C- US1

PCT
Pending
7/23/2009
Methods For Treating Viral Disorders
CU1969C-PCT3

PCT
Pending
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-PCT2

United States
12/508,543
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-US2

United States
61/135,922
7/25/2008
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PPA1

United States
12/508,532
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-US1

PCT
Unknown
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PCT1

Field of Use
Field of Use means the diagnosis, detection, prevention, and treatment of any disease.

IPSCIO Record ID: 26594

License Grant
The Licensor hereby grants to the Licensee an exclusive license under the Licensed Rights to under the Licensed Property.  The Licensee has a unique opportunity to accelerate our development by utilizing intellectual property, drug leads, new research technologies, technical know-how and original scientific concepts derived from 25 years of research achievements relevant to cancer by licensed patent applications and patents.
License Property
CCF Technology shall mean all CCF’s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (I) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).

Provisional Patent Application 60/526,538 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,666 – Methods of Identifying of Modulators of Apoptosis From Parasites and Uses Thereof U.S. Provisional Patent Application 60/526,496 – Methods of Inhibiting Apoptosis Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,667 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,460 – Methods of Protecting Against Radiation Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,461 – Methods of Protecting Against Radiation Using Flagellin U.S. Provisional Patent Application 60/571,149 – Small Molecules Inhibitors of MRP1 and Other Multi drug Transporters U.S. Provisional Patent Application 60/589,637 – Activation of p53 and Inhibition of NF-kB for cancer treatment.

Field of Use
Licensed Field shall mean shall mean the practice, production, manufacture, sale and use of the Licensed Rights for the discovery, development and commercialization of methods, techniques, devices, systems, animals and therapeutics in the field of regulating cell death

CBLC100 series small molecules that restore the activity of p53 tumor suppressor in cancers, including renal cell carcinomas, sarcomas, prostate cancers and other types of malignancies; curaxines and derivatives thereof are representative examples of this category;
CBLB101 series substances of biological nature (i.e., cytokine, chemokines and other secreted molecules) and their bioactive derivatives produced by tumor cells and capable of modulating cell survival; TGFß2 and derivatives thereof and derivatives thereof are representative examples of this category;
CBLB501 series natural factors produced by extracellular parasites and symbiont of humans and other mammalian species and their bioactive derivatives capable of modulating cell survival mechanisms of host cells; flagellin of Salmonella typhimurium and derivatives thereof are representative examples of this category;
CBLC500 series small molecules modulating tumor and normal cell sensitivity to cytotoxic chemicals by altering activity and substrate specificity of multi drug transporters; inhibitors of MRP1 and derivatives thereof are representative examples of this category.

IPSCIO Record ID: 1455

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, a nonexclusive license to Licensee under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to import and have imported, and to offer for sale any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Cancer Vaccines
Evaluation of Anthrax-Toxoid (AT) delivery system for efficiency in generating immune responses directed against tumor tissues in a mouse model system.
Application of the AT delivery system to two murine tumor models.

DNA Delivery Systems
Evaluation of the AT system for efficiency of DNA expression.
12/1/98
Testing of AT system for generating immune responses for Listeria monocytogenes.
12/1/98
Testing of a human pathogen as a DNA vaccine target.

Persistent Viral Infections
Application of the AT system to the (Latent Cytomegalovirus) LCMV model in mice.
12/1/98
Therapy of immunodeficiency virus (SHIV) infected Rhesus macaques and hepatitis B infected non-human primates using the AT system.

U.S. Patent Number 5,591,631 (USSN 08/021,601), entitled, “Anthrax Toxin Fusion Proteins And Related Methods”, Leppla et al., filed February 12, 1993, issued, January 7, 1997.

U.S. Patent Application Serial Number 08/082,849 (CIP of 08/021,601), entitled, “Anthrax Toxin Fusion Proteins And Related Methods”, Leppla et al., filed June 25, 1993.

Patent Application Serial Number 60/025,270, entitled, “Targeting Antigens To The MHC Class I Processing Pathway With An Anthrax Toxin Fusion Protein”, Klimpel et al., filed September 17, 1996.

Field of Use
Field of Use is for vaccines and immunotherapeutics for the prevention or treatment of human and animal diseases.

IPSCIO Record ID: 7497

License Grant
Licensor grants a nonexclusive, worldwide license to Licensee to make, have made, use and sell TGF- beta 2 and TGF-beta Heterodimer as part of a Licensee's Licensed Product (i) for systemic administration for the treatment or prophylaxis of autoimmune diseases or conditions ('Autoimmune Use'), osteoporosis ('Osteoporosis Use'), and soft tissue wound healing (other than the healing of soft tissue wounds caused principally by vascular ischemia or reperfusion injury) ('Wound Healing Uses') and for bone marrow and stem cell protection allowing high dose cytotoxic chemotherapy in cancer patients ('Chemotherapy Use'), and (ii) for systemic or local or regional administration for direct anti-proliferative effects on solid cancerous tumors and lymphomas ('Cancer Use') and for the treatment or prophylaxis of prostatic hypertrophy ('Prostate Use') (collectively these six Uses are referred to as 'Systemic Uses').
Licensee may grant one sublicense under this license only to one other party in any country for each Systemic Use at any one time.
License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence hereto, and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.

IPSCIO Record ID: 203246

License Grant
Licensor, a University, grants an exclusive license under the Patents to make, to have made, use and sell Licensed Products in the Field of Use in the Territory.
License Property
The Licensed Products shall mean products falling within the scope of a Valid Claim or claims of the Patents or made by processes within the scope of a Valid Claim or claims of the Patents.  The patents are for the Method of Enhanced Transmembrane Transport of Exogenous Molecules.

Method of Enhanced Transmembrane Transport of Exogenous Molecules (continuation of P-88080 now abandoned) (biotin, riboflavin) (CIP of 07/331,816, 4/30/89 ABAN) Patent No. 5,108,921

Method of Enhanced Transmembrane Transport of Exogenous Molecules (folate) U.S. Patent No. 5,416,016

Method of Enhanced Transmembrane Transport of Exogenous Molecules (thiamin) U.S. Patent No. 5,635,382

Method for Targeting a Diagnostic Agent to Cells (no transmembrane transport required) U.S. Patent No. 5,820,847

Composition and Method for Tumor Imaging U.S. Patent No. 5,688,488

Folic Acid Derivatives U.S. Nationalized PCT filed 4/17/00

Method of Treatment Using Lignad-Immunogen Conjugates

Field of Use
The Field of Use shall mean All Diagnostic and Imaging Applications and All Therapeutic Applications.  The Licensee is developing targeted therapies for the treatment of cancer and inflammatory diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.